Insight Molecular Diagnostics (IMDX) Cash & Equivalents (2015 - 2026)

Insight Molecular Diagnostics has reported Cash & Equivalents for 12 years, with the latest figure at $28.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 9.03% year-over-year to $28.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (down 9.03% YoY) and the FY2025 annual result came in at $11.6 million, up 34.12% from the prior year.
• Cash & Equivalents advanced to $28.2 million in Q1 2026 per IMDX's latest filing, from $11.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $44.8 million in Q2 2022 and troughed at $433000.0 in Q4 2022.
• A 5-year average of $17.1 million and a median of $13.8 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents jumped 2078.29% in 2023, then sank 75.36% in 2024.
• Over 5 years, Cash & Equivalents stood at $433000.0 in 2022, then surged by 2078.29% to $9.4 million in 2023, then slipped by 8.44% to $8.6 million in 2024, then soared by 34.12% to $11.6 million in 2025, then jumped by 143.46% to $28.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $28.2 million, $11.6 million, and $18.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.